•  

Board of Directors

Our Board

TIAP’s Board is composed of Directors with expertise from within our member institutions and with relevant industry experience. The Board provides crucial governance to TIAP  through its high degree of accountability and rigour of its governance policies. The Directors also serve on Board committees, lending their knowledge and insight to the following areas: Investment, HR and Governance, and Audit and Finance.

 

Photo of Rafi Hofstein Rafi Hofstein President & CEO

Dr. Raphael (Rafi) Hofstein joined Toronto Innovation Acceleration Partners (previously MaRS Innovation) as President and CEO in June 2009. He is currently member of the board of directors of Life Science Ontario and of Clinical Trials Ontario, as well as a member of the Organizing Committee of the Public Policy Forum on Venture Capital and Innovation (part of the Quebec City Conference) and part of the Ontario Health Innovation Council (OHIC).…

Photo of Jessica Chutter Jessica Chutter Managing Director, Chairman of Biotechnology Investment Banking, Morgan Stanley

Jessica is the managing director and chairman of Biotechnology Investment Banking at Morgan Stanley. During Jessica’s 30-year career of building Morgan Stanley’s biotechnology franchise, she has been responsible for $30 billion of capital raising and $65B of strategic transactions. In 2017, transactions include leading financings for Axovant, Biohaven, Editas, Galapagos, RegenxBio and Syndax, aggregating $1Bn in proceeds. …

Photo of Dr. Vivek GoelDr. Vivek Goel PhD, Vice President, Research and Innovation, University of Toronto

Professor Vivek Goel was appointed Vice President, Research and Innovation of the University of Toronto in December, 2014. Professor Goel is a distinguished scholar with an extensive background in teaching, research and university administration. He obtained his medical degree from McGill University and completed post-graduate medical training in Community Medicine at the University of Toronto. Dr.…

Photo of Angus J. Grant PhD Angus J. Grant PhDCorporate Vice President, Business Development, Celgene Corporation

Angus Grant joined Celgene as Vice President North American Regulatory Affairs in 2006, in the Summit NJ Headquarters.  In 2008, Angus moved to London as Head of Europe RA for 3 years. Angus returned to the Summit NJ Headquarters as VP, Business Development and Global Alliances, in 2011, where he has since completed multiple innovative deals and has in tandem built the Alliance Management function, which now manages over 50 collaborations and investments with pharmaceutical and biotech partners.…

Photo of Laurie Harrison Laurie Harrison Vice President, CFO

Ms. Harrison has 30 years of experience in Ontario healthcare organizations providing strategic and operational leadership in Finance, Business Development, Treasury, Strategic Planning, Human Resources, and Operations Ms. Harrison has a BSc degree in Business Administration from the University of Tennessee as well as an MBA from Northwestern (Kellogg) and York Universities.  She holds the Certified Public Accountant designation. …

Photo of Grace Lee Reynolds Grace Lee Reynolds Chief Business Officer & Secretary-Treasurer, MaRS Discovery District

Grace Lee Reynolds oversees the operations portfolio, which includes real estate & events, data & technology, finance, legal, and corporate development functions at MaRS. She is also responsible for governance and financial strategy and accountability, and serves as the Secretary-Treasurer of the Board. Committed to organizations that drive meaningful social impact, she has held leadership roles in healthcare and charitable organizations.…

Photo of Mario Piccinin Mario Piccinin MBA, CPA, CA – Partner, Ernst & Young LLP

Mario is an Audit Partner and the Greater Toronto Area Life Science Leader at EY with 26 years of experience providing audit and business advisory services to private and public companies in a variety of industries. His practice is focused on Life Science companies including Healthcare, Diagnostic, Med Tech, Pharma and Biotechnology companies. Mario has had extensive hands on experience working with companies in all aspects of their life cycles, from start-up to mature organizations, helping them achieve their goals.…

Photo of Dr. Laszlo RadvanyiDr. Laszlo Radvanyi President & Scientific Director

Dr. Laszlo Radvanyi brings a strong oncology research background in academia as well as leadership experience in international pharma and biotech, making him an ideal leader for OICR. Laszlo was educated at the University of Toronto, earning a PhD in Clinical Biochemistry in 1996. Laszlo joined OICR from EMD Serono (Merck KGaA, Darmstadt, Germany), where he was Senior Vice President Global Head of the Immuno-Oncology (IO) Translational Innovation Platform (TIP) and Senior Scientific Advisor for Immunology and IO.…

Photo of Mike Rhodin Mike Rhodin (Retired) Senior Vice President of IBM; Founder of the Watson Group

Mike Rhodin recently retired from IBM after 33 years,  and 7 years as a corporate officer.  Most recently he was responsible for founding the IBM Watson business units.  Prior to that,  Mike founded IBM’s solution units around their Smarter Planet initiatives including Smarter Cities,  Smarter Commerce and Smarter Analytics.  During the last financial crisis,  Mike was based in Zurich, Switzerland and responsible for most of IBM’s European operations.…

Photo of Dr. Andy J. SmithDr. Andy J. Smith President & CEO, Sunnybrook Health Sciences Centre
Photo of Shermaine Tilley Shermaine Tilley Dr. Shermaine Tilley, Managing Partner, CTI Life Sciences Fund

Since joining CTI Life Sciences Fund (CTI LSF) at its inception in 2006, Shermaine has played a critical role in each of the investments made by the Fund, but particularly by leading investments in Medicago - acquired by Mitsubishi Tanabe for $357 M in 2013 - as well as those in IMV (IMV: Nasdaq & TSX) and Zymeworks (ZYME: NYSE & TSX).…

Photo of Dr. Bradly G. WoutersDr. Bradly G. Wouters Executive Vice President, Science & Research

Dr. Bradly Wouters is an internationally recognized leader and cancer researcher. He became Executive Vice President of Science and Research at UHN in 2016 and prior to that served as the Interim Director of Research at the Princess Margaret Cancer Centre since 2014. He joined UHN in 2008 as Senior Scientist and Director of the Princess Margaret Hypoxia Program, and has held faculty appointments at the University of Toronto in the Department of Medical Biophysics and the Department of Radiation Oncology since that time.…

Photo of Dr. Catherine ZahnDr. Catherine Zahn President & CEO

Dr. Zahn was appointed President and CEO of the Centre for Addiction and Mental Health (CAMH) in 2009.  CAMH is Canada’s leading mental health hospital and the country’s largest academic health science centre focused on mental illness. She received her MD (honours) from the Faculty of Medicine at the University of Toronto (U of T), where she completed her residency training in neurology. …